Microsoft powerpoint - milan ccic handout notcutt handout
The Practical Use of Cannabinoids in the Dr Willy Notcutt, FRCA, FFPMRCA James Paget Hospital GREAT YARMOUTH, Norfolk, UK william.notcutt@jpaget.nhs.uk
• The endocannabinoid system is a therapeutic
target yet to be properly explored for pain management
• Cannabinoids are a new medicine to clinicians
– New role, effects, benefits, side-effects
But…• Many of our patients are already using street
Cannabis for symptom control using similar materials but different delivery systems.
Focusing on Medicinal Products in use. Selecting Patients Pain Problems
• Neuropathic (L)
– Central (L)
– Peripheral (L)
• Cancer Pain (L)
• Other Areas
– Anti-emetic, CINV
• Nabilone (Cesamet) : synthetic THC analogue
• Dronabinol (Marinol): synthetic THC 2.5/5/10mg
– Appetite stimulation in AIDS– CINV nausea and vomiting
• Nabiximols (Sativex): plant extracted THC/CBD
– MS related spasticity/spasms– Cancer Pain– Neuropathic Pain
• Bedrocan (plant) and Namisol (plant THC tablet)
Which Patients ?: Complex not
others are ineffective, insufficient or not tolerated (eg. Baclofen, Tizanidine Gabapentin, Opiates)
• Occasional recreational use when young
• Smoking a cannabis cigarette at night to
• Smoking cannabis 6x /day
• Regular recreational use
• Dependency history
– IHD– Hypertension– Dysrhythmias– Postural hypotension– Mixture of Medications
– Tissue solubility, self administration
– Epilepsy– Psychosis, Endogenous Depression,
– Addiction/Abuse/Alcohol problems– Note: MS is associated with Suicide,
Preparing the Patient Side-Effects
–Importance of Titration
– Psychosis– Addiction– Cognitive Impairment, Memory
– Increased appetite (Munchies)– Excessive Hypotonia
• What happens when an accident occurs?
1 “joint” equivalent to get “high”;
Tracking tasks are affected Reaction times increased
therefore drive more slowly – unlike alcohol
Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis
Acute cannabis consumption nearly doubles the risk of a collision
resulting in serious injury or death; this increase was most evident for studies of high quality, case-control studies, and studies of fatal collisions
The influence of cannabis use on the risk of minor collisions remains unclear
Any impairment is probably well within the range of (or lower than) what is currently produced by pharmaceutical agents which are commonly used for similar conditions. (Opiates, Benzodiazepines,Tricyclic Antidepressants, Baclofen, etc)
Hadorn. The Medicinal Uses of Cannabis and CannabinoidsPrescribing Cannabinoids
• To increase appetite, 1-2 times a day – bd
• The usual dosage of Cesamet is 1 mg or 2
• Nabilone should be given 1 to 3 hours
before chemotherapy, and a dose given the night before
• Nabilone may be given for the entire
course of each chemotherapy cycle and, if needed, for 48 hours after the last dose of each cycle.
vaporizer can be used to inhale cannabis vapor.
Further Management
• Every Patient is Different in Symptoms and Response
– Consider NRS (Numerial Rating Score 0-10) etc. What If…?
• Patient needs to come into hospital for surgery
• Patient is admitted for a medical emergency
• Patient wants to go abroad on holiday
• Patient wants a break from the medicine
• Ensure patients return empty bottles?
personal, legitimate recreational drug source
• The “High” is better with smoking
• Cost of the Medicines
• Cost of other MS medicines • Attitudes to Cannabinoids
Biological, clinical, and ethical advances of placebo eff ects Damien G Finniss, Ted J Kaptchuk, Franklin Miller, Fabrizio Benedetti Lancet 2010; 375: 686–95 For many years, placebos have been defi ned by their inert content and their use as controls in clinical trials and University of Sydney Pain treatments in clinical practice. Recent research shows that placebo eff ec
“¿Por qué los alemanes son como son?” Alemania desde dentro En colaboración con el Barcelona Centre for International Affairs (CIDOB) Jueves, 24 de octubre y viernes, 25 de octubre 2013 Jueves, 24 de octubre de 2013 Introducción y bienvenida CARLES A. GASÒLIBA Presidente del CIDOB BERNHARD BRASACK Cónsul General de Alemania Alemania después de las el